PharmiNews

The Directory of Pharma Companies and News

Summit Therapeutics

Summit Therapeutics logo
Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection.
Category: Biotech
Category: Biotech

Summit Therapeutics News

DateNews
2016-12-15Financial Results for the Third Quarter Ended 31 October 2016 (PDF)
2016-12-15Summit Reports Financial Results for the Third Quarter Ended 31 October 2016 and Operational Progress (PDF)
2016-11-16Summit Enrols Patients in the United States Into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients With DM... (PDF)
2016-10-06Summit Presents Preclinical DMD Data at 21st Congress of World Muscle Society (PDF)
2016-10-04Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement (PDF)
2016-09-27Summit Receives Rare Pediatric Disease Designation from US FDA for Ezutromid in Treatment of DMD (PDF)
2016-09-26Summit Receives Fast Track Designation from US FDA for Ezutromid in the Treatment of DMD (PDF)
2016-09-12Summit Launches Online Resource on Utrophin Modulation for the Duchenne Muscular Dystrophy Community (PDF)
2016-09-08Financial Results for the Second Quarter Ended 31 July 2016 (PDF)
2016-09-07Summit Therapeutics to Present at 18th Annual Rodman & Renshaw Global Investment Conference (PDF)
2016-08-09Positive Phase 1 Data and Outlined Route to Market Strategy for Ezutromid (PDF)
2016-08-05Summit Therapeutics to Present at Canaccord Genuity Growth Conference (PDF)
2016-06-20Summit’s Ridinilazole Preserves Microbiome During Treatment of C. Difficile Infection (PDF)
2016-06-17First Patient Enrolled in Summit’s PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys with DMD (PDF)
2016-06-16Summit to Present at JMP Securities Life Sciences Conference (PDF)
2016-06-08Summit Therapeutics to Host Utrophin R&D Day 15 June 2016 (PDF)
2016-06-02Financial Results from the First Quarter Ended 30 April 2016 (PDF)
2016-06-02Financial Results for the First Quarter Ended 30 April 2016 (PDF)
2016-05-23Summit to Present Phase 2 CoDIFy Trial Data Highlighting Ridinilazole’s Preservation of the Microbiome in CDI Patients a... (PDF)
2016-05-10Financial Results for Fourth Quarter and Fiscal Year Ended 31 January 2016 (PDF)
2016-04-28Further US Patent Granted for CDI Antibiotic Ridinilazole (PDF)
2016-04-26Summit’s IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid (PDF)
2016-04-11Positive Results from Phase 2 CoDIFy Trial Presented at ECCMID (PDF)
2016-04-06Summit to Present at 15th Annual Needham Healthcare Conference (PDF)
2016-03-30Positive Interim Data from Ongoing Phase 1 Trial Testing New Formulation of SMT C1100 (PDF)
2016-03-29Summit to Present Additional Data from Phase 2 CoDIFy Trial (PDF)
2016-03-15Publication on Biomarkers to Quantify Utrophin Protein and Regeneration of Muscle Fibres in DMD (PDF)
2016-03-07Ridinilazole Preserves the Gut Microbiome of Patients with C. difficile Infection in Phase 2 Trial (PDF)
2016-02-24Publication of Preclinical Data Showing Ridinialzole Reduces C. difficile Toxins that Drive Disease Symptoms (PDF)
2016-02-24Publication of Preclinical Data Showing Ridinilazole Reduces C. difficile Toxins that Drive Disease Symptoms (PDF)
2016-02-17Summit Therapeutics to Participate in SunTrust Robinson Humphrey’s 2016 Orphan Drug Day (PDF)
2016-02-03Summit to Present at 18th Annual BIO CEO & Investor Conference (PDF)
2016-01-21Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Pati... (PDF)
2016-01-19Grant of Key European Patent for Novel Antibiotic Ridinilazole for Treatment of CDI (PDF)
2015-12-17Third Quarter Financial Results (PDF)
2015-12-10Summit to Participate in JMP Securities DMD Forum (PDF)
2015-12-03Summit to Present at the 26th Annual Oppenheimer Healthcare Conference (PDF)
2015-12-02Achievement of First Milestone in Strategic Alliance with University of Oxford (PDF)
2015-11-25Summit to Present at the 27th Piper Jaffray Healthcare Conference (PDF)
2015-11-23Positive Top-line Phase 2 Data of Ridinilazole in CDI (PDF)
2015-11-17Summit and the University of Oxford Extend Strategic Alliance for Development of Utrophin Modulators (PDF)
2015-09-30Presentation of Additional Data from Phase 1b Trial of SMT C1100 in DMD Patients at 2015 WMS Congress (PDF)
2015-09-24Summit Therapeutics to Present Clinical and Preclinical Data at WMS Congress 2015 (PDF)
2015-09-18Presentation of New Preclinical Data on SMT19969 at ICAAC 2015 (PDF)
2015-09-10Completion of Targeted Enrolment for SMT19969 Phase 2 Trial for CDI (PDF)
2015-09-02Dr Ralf Rosskamp Appointed as Chief Medical Officer (PDF)
2015-08-27Second Quarter and Half-Year Financial Results (PDF)
2015-08-17Top-line Results from Phase 1b Clinical Trial of SMT C1100 in DMD (PDF)
2015-07-13Publication of Preclinical Data on the Disease Modifying Potential of Utrophin Modulation in DMD (PDF)
2015-07-08Receipt of FDA Fast Track Designation for Novel CDI Antibiotic SMT19969 (PDF)
2015-07-07Grant of Key Patent by European Patent Office for Utrophin Modulator SMT C1100 (PDF)
2015-06-19Summit Therapeutics to Present New Preclinical Data on Utrophin Modulator Programme at PPMD Connect Conference (PDF)
2015-06-11First Quarter Financial Results (PDF)
2015-06-05Notice of First Quarter Financial Results (PDF)
2015-05-08US Annual Report Form 20-F Filed with SEC (PDF)
2015-05-06Financial Results for the Year Ended 31 January 2015 (PDF)
2015-05-01Notice of Full Year Financial Results (PDF)
2015-04-30Grant of US Patent for Novel CDI Antibiotic SMT19969 (PDF)
2015-04-07Summit to Present at Needham & Co Healthcare Conference (PDF)
2015-03-24Exercise of Options (PDF)
2015-03-18Exercise of Over-allotment Option (PDF)
2015-03-10Summit Announce the Close of its US Initial Public Offering (PDF)
2015-03-05Summit Announces the Pricing of US Initial Public Offering and NASDAQ Listing (PDF)
2015-02-23Summit File Amended Registration Statement for Proposed NASDAQ Listing and US Offering (PDF)
2015-02-23Mr David Wurzer Appointed as Non-Executive Director (PDF)
2015-02-20First Patients Dosed in Phase 1b Modified Diet Clinical Trial of SMT C1100 for Treatment of DMD (PDF)
2015-02-20Confirmation of Name Change to Summit Therapeutics plc (PDF)
2015-02-19Result of General Meeting (PDF)
2015-02-02Filing of Registration Statement for Proposed NASDAQ Listing and US Offering of ADS (PDF)
2015-02-02Third Quarter Results for the Nine Months Ended 31 October 2014 (PDF)
2015-01-23Award of Share Options (PDF)
2014-12-19Summit Considering Potential US Registered Public Offering and Stock Exchange Listing (PDF)
2014-12-11Summit Receives Regulatory Approval to Initiate Modified Diet Clinical Trial in DMD Patients (PDF)
2014-12-03Director Change (PDF)
2014-09-19Ms Valerie Andrews Appointed as a Non-Executive Director (PDF)
2014-09-08New Preclinical Data on SMT19969 Reported at 54th ICAAC Meeting (PDF)
2014-09-04Interim Results for Six Months Ended 31 July 2014 (PDF)
2014-08-07Summit to Present at Canaccord Genuity 34th Annual Growth Conference (PDF)
2014-07-18Update on Capital Reorganisation (PDF)
2014-07-09FDA Grants QIDP Designation to SMT19969 for Treatment of CDI (PDF)
2014-07-07New Data from Phase 1b Clinical Trial of SMT C1100 Reported at 13th ICNMD (PDF)
2014-07-03AGM Statement (PDF)
2014-07-03First Patient Dosed in a Phase 2 Clinical Trial of SMT19969 (PDF)
2014-07-03Result of 2014 Annual General Meeting (PDF)
2014-06-23Erik Ostrowski Appointed as Chief Financial Officer (PDF)
2014-06-19Summit to Present at JMP Securities Healthcare Conference (PDF)
2014-06-17Summit Establishes Operations in Cambridge, Massachusetts (PDF)
2014-06-03Notice of Annual General Meeting (PDF)
2014-05-30Leopoldo Zambeletti Appointed as a Non-Executive Director (PDF)
2014-05-21Preliminary Results from Phase 1b Trial of SMT C1100 for DMD (PDF)
2014-05-12New Positive Data on SMT19969 Presented at 24th ECCMID (PDF)
2014-04-30Preliminary Financial Results for Year Ended 31 January 2014 (PDF)
2014-03-18Clearance of IND Application for Phase 2 Study of SMT19969 for CDI (PDF)
2014-02-26Result of Offer for Subscription to Qualifying Shareholders (PDF)
2014-02-26Presentation at 34th Cowen & Company Healthcare Conference (PDF)
2014-02-11Proposed Placing and Offer for Subscription (PDF)
2013-12-09First Patient Dosed in a Phase 1b Clinical Trial of SMT C1100 for Treatment of DMD (PDF)
2013-11-25Summit and University of Oxford Enter Strategic Alliance in DMD (PDF)
2013-11-05Summit and Joining Jack Enter Funding Agreement to Support Biomarker Development for DMD (PDF)
2013-11-01Summit Receive Regulatory Approval to Start Phase 1b Clinical Trial of SMT C1100 (PDF)
2013-09-30Clinical and Biomarker Development Programme for DMD Presented at 18th WMS Congress (PDF)
2013-09-26Appointment of Nominated Adviser (PDF)
2013-09-11New Data on SMT19969 Reported at 53rd ICAAC Meeting (PDF)
2013-09-04Summit to Present New Data on C difficile Antibiotic at ICAAC 2013 (PDF)
2013-08-28Grant of Key Composition of Matter Patent for SMT C1100 in the Treatment of DMD (PDF)
2013-08-23Exercise of Warrants (PDF)
2013-08-22Interim Results for Six Months Ended 31 July 2013 (PDF)
2013-08-21Notice of Interim Results (PDF)
2013-08-07US Patent Granted for Utrophin Modulator SMTC1100 in Treatment of DMD (PDF)
2013-08-06Summit to Present at Wedbush Securities Life Sciences Conference (PDF)
2013-07-31£2.4m Award from the UK Biomedical Catalyst Fund to Support DMD Programme (PDF)
2013-07-18Funding Agreement Signed with Save Our Sons to Support Development of DMD Programme (PDF)
2013-07-03Placing to Raise GBP4.5m and Offer for Subscription to Qualifying Shareholders (PDF)
2013-07-03Related Party Transaction (PDF)
2013-07-02Change of Registered Address (PDF)
2013-06-17Clinical Milestone Achieved to Trigger Payment from Wellcome Trust to Fund CDI Antibiotic (PDF)
2013-06-12Appointment of Dr David Roblin as Chief Medical Officer (PDF)
2013-06-06Result of 2013 Annual General Meeting and Board Change (PDF)
2013-06-062013 Annual General Meeting Statement (PDF)
2013-04-24Positive Phase 1 Clinical Trial Results on SMT 19969 Reported (PDF)
2013-04-17Publication of Abstracts for ECCMID 2013 Conference (PDF)
2013-04-11Preliminary Financial Results for Year Ended 31 January 2013 (PDF)
2013-04-09Notice of Preliminary Results (PDF)
2013-03-21Clinical Plans Outlined for Utrophin Modulator SMT C1100 for Treatment of DMD (PDF)
2013-03-11New Data Reported from Preclinical Efficacy Study on OGA Inhibitors for Alzheimer’s and Related Diseases (PDF)
2013-03-01Board of Director Change (PDF)
2013-02-13Advisory Board Formed to Support DMD Programme (PDF)
2013-02-06Funded Collaboration to Develop Utrophin Biomarkers (PDF)
2013-01-25Nomura Code Securities Appointed as Nomad and Joint-broker (PDF)
2012-11-22Mr Jim Mellon and Dr Frank Armstrong Appointed as Non-Executive Directors (PDF)
2012-11-20Adviser Change of Name (PDF)
2012-11-14Summit to Present at Proactive Investors One2One Investor Forum on 22 November 2012 (PDF)
2012-11-07Repeat dosing data announced from Phase 1 trial of SMT C1100 for DMD (PDF)
2012-10-31Initiation of Phase 1 Clinical Trial of SMT 19969 (PDF)
2012-10-22£4.0m Translational Award from Wellcome Trust (PDF)
2012-10-15Launch of new corporate website (PDF)
2012-09-11BMS Collaboration (PDF)
2012-09-06Strategy Review (PDF)
2012-09-06Interim Results 2012 (PDF)
2012-08-02TSB Award Offer (PDF)
2012-07-18Result of AGM (PDF)
2012-07-18AGM 2012 (PDF)
2012-07-17AAIC 2012 (PDF)
2012-06-29Connect Conference 2012 (PDF)
2012-06-14Director Dealings G Elliott (PDF)
2012-06-12SMT C1100 Phase 1 Milestone (PDF)
2012-06-01Notice of AGM (PDF)
2012-05-25SMT C1100 Phase 1 Initiation (PDF)
2012-05-10Grant of Options (PDF)
2012-04-24CTA Approval (PDF)
2012-04-23Application to Trading (PDF)
2012-04-20Result of GM (PDF)
2012-04-16Company Statement (PDF)
2012-04-05Executive Dealings (PDF)
2012-04-04Proposed Placing Circular (PDF)
2012-04-04Research Update SMT 19969 Preclinical Completion (PDF)
2012-04-04Appointment of Glyn Edwards as CEO (PDF)
2012-04-04Preliminary Results 2012 (PDF)
2012-04-04Placing (PDF)
2012-03-06Research Update OGA Programme (PDF)
2012-02-14Clinical Trial Update (PDF)
2011-12-19SMT C1100 Research Agreement Funding (PDF)
2011-11-24US Orphan Drug Designation for SMT (PDF)
2011-11-01Appointment of Joint Broker (PDF)
2011-09-19ICAAC Meeting Attendance (PDF)
2011-08-23Interim Results (PDF)
2011-07-19ICAD Poster (PDF)
2011-06-30Research Update OGA (PDF)
2011-05-12Nomination of SMT 19969 (PDF)
2011-05-05Publication of DMD PLoS Paper (PDF)
2011-04-15Notice of AGM FINAL (PDF)
2011-03-30Preliminary Results (PDF)
2011-03-24Notice of Prelims (PDF)
2011-03-14Research Update DMD (PDF)
2010-10-13Director PDMR Dealings (PDF)
2010-10-12C diff Proof of Concept (PDF)
2010-08-03BMRN (PDF)
2010-06-29Conference Announcement (PDF)
2010-03-30Research Update (PDF)
2010-03-05Pre-close Dealings March SGD (PDF)
2010-03-05Pre-close Dealings (PDF)
2010-02-24Trading Update (PDF)
2010-01-12DMD Phase I Clinical Trial Start (PDF)
2009-12-30Result of Placing & Open Offer (PDF)
2009-12-11Wellcome Grant Award (PDF)
2009-12-11Placing & Open Offer (PDF)
2009-10-23Interim Results 2009 (PDF)
2009-10-21Notice of Interims (PDF)
2009-09-02Dextra Divestment (PDF)
2009-08-20AGM Result 2009 (PDF)
2009-05-29Orient Agreements & Restructuring Update (PDF)
2009-05-07Zebrafish Divestment (PDF)
2009-03-23Raymond Spencer Appointment (PDF)
2009-03-23Directorate Change (PDF)
2009-02-20Financial Update (PDF)
2009-01-23Colin Wall (PDF)
2009-01-06Evolva Licensing Agreement (PDF)
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.